Navigation Links
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Date:3/13/2008

trial (4Q08).

-- ENMD-2076 is an oral selective kinase inhibitor with a unique kinase

profile, including antiproliferative activity and inhibition of

angiogenesis. ENMD-2076 has demonstrated potent antitumor activity as a

single agent in multiple preclinical models, including tumor regression

in breast, colon, and leukemia models without cardiovascular effects.

ENMD-2076 is a unique-in-class compound that inhibits both Aurora A and

growth factor receptors critical to angiogenesis.

-- EntreMed's IND has been accepted by the FDA and a Phase 1 study in

solid tumors is expected to enroll patients in early 2Q08. EntreMed has

been selected for an oral presentation on ENMD-2076 during the American

Association for Cancer Research's "Drugs on the Horizon" symposium to

be held during the AACR annual meeting in April. ENMD-2076 milestones

for 2008 include initiating a Phase 1 trial in solid tumors (1Q08);

initiating a Phase 1 trial in hematological tumors (3Q08/4Q08); and

entering into a development alliance (2H08/1H09).

-- EntreMed plans to discontinue development of 2ME2 (Panzem(R) NCD) for

oncology. Modest antitumor activity has been shown across most of the

clinical studies, yet there is not a clear development path that would

narrow the indications for larger randomized studies. Additional trial

costs, the high doses required for use in oncology, and

manufacturing/process development expenditures would together require

the commitment of a disproportionate amount of resources and limit

clinical development efforts on the remainder of the pipeline. Patients

still on clinical oncology trials, however, will continue to receive

Panzem(R) NCD.

-- EntreMed plans to move 2ME2 forward in rheumatoid arthritis based on

the knowledge gained from the oncolo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
2. EntreMed to Present at BIO CEO and Investor Conference
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
5. EntreMed Appoints Senior Vice President of Research and Development
6. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
7. Arpida Announces Full Year 2007 Financial Results
8. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
9. WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
10. Exelixis Announces March 17 Webcast of Presentation at the Cowen and Company Annual Health Care Conference
11. deCODE Genetics Announces Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Genomics and Proteomics Analytical Instruments Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Genomics is the study of ... study of the structure and functions of proteomes or ... tools and technology. Genomics involves the mapping of genes ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... chemists have developed a new model to predict the ... finding could help inform the design of tailored nano-structures, ... fields, including the remote sensing of atmospheric pollutants and ... nano-particles play a key role in atmospheric processes as ...
... 24, 2011 ValGenesis, Inc., an industry-leading provider ... announced the availability of its industry-proven solution as ... hosted on MUSA,s Validated Cloud. ValGenesis ... solution accessible via the Internet through MUSA,s Validated ...
... 24, 2011 Reportlinker.com announces that a new market ... Quantum Dots: Technologies and Global Markets ... for quantum dots (QDs) in 2010 was worth an ... to grow over the next 5 years at a ...
Cached Biology Technology:UBC researchers develop new model to predict the optical properties of nano-structures 2Announcing ValGenesis On-Demand SaaS Solution 2Announcing ValGenesis On-Demand SaaS Solution 3Reportlinker Adds Quantum Dots: Technologies and Global Markets 2Reportlinker Adds Quantum Dots: Technologies and Global Markets 3Reportlinker Adds Quantum Dots: Technologies and Global Markets 4Reportlinker Adds Quantum Dots: Technologies and Global Markets 5Reportlinker Adds Quantum Dots: Technologies and Global Markets 6Reportlinker Adds Quantum Dots: Technologies and Global Markets 7Reportlinker Adds Quantum Dots: Technologies and Global Markets 8Reportlinker Adds Quantum Dots: Technologies and Global Markets 9Reportlinker Adds Quantum Dots: Technologies and Global Markets 10Reportlinker Adds Quantum Dots: Technologies and Global Markets 11Reportlinker Adds Quantum Dots: Technologies and Global Markets 12Reportlinker Adds Quantum Dots: Technologies and Global Markets 13Reportlinker Adds Quantum Dots: Technologies and Global Markets 14Reportlinker Adds Quantum Dots: Technologies and Global Markets 15Reportlinker Adds Quantum Dots: Technologies and Global Markets 16Reportlinker Adds Quantum Dots: Technologies and Global Markets 17Reportlinker Adds Quantum Dots: Technologies and Global Markets 18Reportlinker Adds Quantum Dots: Technologies and Global Markets 19Reportlinker Adds Quantum Dots: Technologies and Global Markets 20
(Date:7/24/2014)... on average over a 35 year period in which ... impact of humans on declining animal numbers. This decline ... insects, spiders, crustaceans, slugs and worms bring to our ... decomposition for nutrient cycling, water filtration and human health. ... led by UCL, Stanford and UCSB, focused on the ...
(Date:7/24/2014)... two factors that characterize sustainable university and college ... qualified physics teachers. Specifically, one or more faculty ... in combination with institutional motivation and commitment can ... Engineering and Math (STEM) teacher shortages are especially ... way for institutions seeking to increase the number ...
(Date:7/24/2014)... current biodiversity, the product of 3.5 billion years of ... history of life. But it may be reaching a ... literature and analysis of data published in Science ... loss and decline of animals is contributing to what ... sixth mass biological extinction event. , Since 1500, more ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... Biologists at the University of Pennsylvania studying oocytes in ... have demonstrated an unusual behavior in microRNA, or miRNA, ... the differentiated oocyte into pluripotent blastomeres of the embryo. ... RNAs, the so-called dark matter of the biological world. ...
... North Carolina State University have developed a "smart coating" that ... off infection. When patients have hip, knee or dental ... reject the implant. But the smart coating developed at NC ... implant. The coating creates a crystalline layer next to the ...
... release is available in Spanish . , ... beverages owe much of their smooth, delicious flavor to malt. ... at the Agricultural Research Service,s (ARS) malting barley laboratory in ... There, chemist Mark Schmitt and plant physiologist Allen Budde ...
Cached Biology News:Penn biologists determine microRNA activity is suppressed in mouse ovum 2Smart coating opens door to safer hip, knee and dental implants 2Secrets to superb malting barleys explored by ARS researchers 2
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
...
Rat Epidermal Keratinocytes (REK) (>500,000 cells)...
... Pro-OpioMelanoCortin (POMC) has long been ... prime precursor to a multiplicity of ... (-LPH), -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) ... very well-conserved molecule, being found in ...
Biology Products: